## Guillermo N Armaiz-Pena

## List of Publications by Citations

 $\textbf{Source:} \ https://exaly.com/author-pdf/6741146/guillermo-n-armaiz-pena-publications-by-citations.pdf$ 

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

60 papers

4,973 citations

36 h-index

g-index

90 ext. papers

5,712 ext. citations

10.5 avg, IF

4.4 L-index

| #  | Paper  | IF            | Citations |
|----|--|---------------|-----------|
| 60 | Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. <i>Nature Medicine</i> , <b>2006</b> , 12, 939-44   | 50.5          | 836       |
| 59 | Paraneoplastic thrombocytosis in ovarian cancer. New England Journal of Medicine, 2012, 366, 610-8   | 59.2          | 505       |
| 58 | Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 3423-30           | 12.9          | 337       |
| 57 | Regulation of tumor angiogenesis by EZH2. Cancer Cell, 2010, 18, 185-97  | 24.3          | 290       |
| 56 | Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. <i>Journal of Clinical Investigation</i> , <b>2010</b> , 120, 1515-23                     | 15.9          | 192       |
| 55 | Metabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancer. <i>Molecular Systems Biology</i> , <b>2014</b> , 10, 728                            | 12.2          | 178       |
| 54 | Surgical stress promotes tumor growth in ovarian carcinoma. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 2695-7   | <b>02</b> 2.9 | 160       |
| 53 | Src activation by Endrenoreceptors is a key switch for tumour metastasis. <i>Nature Communications</i> , <b>2013</b> , 4, 1403   | 17.4          | 141       |
| 52 | Stress effects on FosB- and interleukin-8 (IL8)-driven ovarian cancer growth and metastasis. <i>Journal of Biological Chemistry</i> , <b>2010</b> , 285, 35462-70                          | 5.4           | 131       |
| 51 | Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression. <i>Nature Communications</i> , <b>2014</b> , 5, 5202  | 17.4          | 130       |
| 50 | Neuroendocrine modulation of signal transducer and activator of transcription-3 in ovarian cancer. <i>Cancer Research</i> , <b>2007</b> , 67, 10389-96                                     | 10.1          | 119       |
| 49 | Stress hormones regulate interleukin-6 expression by human ovarian carcinoma cells through a Src-dependent mechanism. <i>Journal of Biological Chemistry</i> , <b>2007</b> , 282, 29919-26 | 5.4           | 108       |
| 48 | Therapeutic Targeting of ATP7B in Ovarian Carcinoma. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 3770-80   | 12.9          | 103       |
| 47 | Functional significance of VEGFR-2 on ovarian cancer cells. <i>International Journal of Cancer</i> , <b>2009</b> , 124, 1045-53  | 7.5           | 100       |
| 46 | Neuroendocrine modulation of cancer progression. <i>Brain, Behavior, and Immunity</i> , <b>2009</b> , 23, 10-5   | 16.6          | 95        |
| 45 | Neuroendocrine influences on cancer progression. <i>Brain, Behavior, and Immunity</i> , <b>2013</b> , 30 Suppl, S19-2  | <b>5</b> 16.6 | 89        |
| 44 | A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer. <i>Nature Communications</i> , <b>2016</b> , 7, 11169  | 17.4          | 83        |

## (2011-2014)

| 43 | 2UOMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity. <i>Nature Communications</i> , <b>2014</b> , 5, 3459 | 17.4 | 81 |
|----|---|------|----|
| 42 | Calcium-dependent FAK/CREB/TNNC1 signalling mediates the effect of stromal MFAP5 on ovarian cancer metastatic potential. <i>Nature Communications</i> , <b>2014</b> , 5, 5092 | 17.4 | 79 |
| 41 | Long Noncoding RNA Ceruloplasmin Promotes Cancer Growth by Altering Glycolysis. <i>Cell Reports</i> , <b>2015</b> , 13, 2395-2402   | 10.6 | 75 |
| 40 | Hypoxia-upregulated microRNA-630 targets Dicer, leading to increased tumor progression. <i>Oncogene</i> , <b>2016</b> , 35, 4312-20   | 9.2  | 70 |
| 39 | Targeting c-MYC in Platinum-Resistant Ovarian Cancer. <i>Molecular Cancer Therapeutics</i> , <b>2015</b> , 14, 2260-9   | 6.1  | 68 |
| 38 | FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal.<br>Journal of Clinical Investigation, <b>2016</b> , 126, 1885-96               | 15.9 | 68 |
| 37 | Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches. <i>Cancer and Metastasis Reviews</i> , <b>2015</b> , 34, 19-40                                 | 9.6  | 62 |
| 36 | Erythropoietin Stimulates Tumor Growth via EphB4. Cancer Cell, 2015, 28, 610-622  | 24.3 | 60 |
| 35 | Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 5437-46  | 12.9 | 58 |
| 34 | Functional roles of Src and Fgr in ovarian carcinoma. Clinical Cancer Research, <b>2011</b> , 17, 1713-21   | 12.9 | 57 |
| 33 | Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models. <i>Cancer Biology and Therapy</i> , <b>2010</b> , 9, 176-82                                      | 4.6  | 56 |
| 32 | Adrenergic regulation of monocyte chemotactic protein 1 leads to enhanced macrophage recruitment and ovarian carcinoma growth. <i>Oncotarget</i> , <b>2015</b> , 6, 4266-73   | 3.3  | 56 |
| 31 | Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 7034-7046                             | 12.9 | 52 |
| 30 | Sustained adrenergic signaling leads to increased metastasis in ovarian cancer via increased PGE2 synthesis. <i>Oncogene</i> , <b>2016</b> , 35, 2390-7                       | 9.2  | 51 |
| 29 | Monocyte subpopulations in angiogenesis. <i>Cancer Research</i> , <b>2014</b> , 74, 1287-93   | 10.1 | 48 |
| 28 | Adrenergic Stimulation of DUSP1 Impairs Chemotherapy Response in Ovarian Cancer. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 1713-24                                  | 12.9 | 47 |
| 27 | Sustained Adrenergic Signaling Promotes Intratumoral Innervation through BDNF Induction. <i>Cancer Research</i> , <b>2018</b> , 78, 3233-3242                                 | 10.1 | 46 |
| 26 | Targeting SRC in mucinous ovarian carcinoma. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 5367-78  | 12.9 | 38 |

| 25                   | Silencing of p130cas in ovarian carcinoma: a novel mechanism for tumor cell death. <i>Journal of the National Cancer Institute</i> , <b>2011</b> , 103, 1596-612   | 9.7                             | 38                     |
|----------------------|--|---------------------------------|------------------------|
| 24                   | Focal adhesion kinase: an alternative focus for anti-angiogenesis therapy in ovarian cancer. <i>Cancer Biology and Therapy</i> , <b>2014</b> , 15, 919-29  | 4.6                             | 33                     |
| 23                   | Role of Increased n-acetylaspartate Levels in Cancer. <i>Journal of the National Cancer Institute</i> , <b>2016</b> , 108, djv426  | 9.7                             | 32                     |
| 22                   | Estrous cycle modulates ovarian carcinoma growth. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 2971-8   | 12.9                            | 30                     |
| 21                   | Metronomic docetaxel in PRINT nanoparticles and EZH2 silencing have synergistic antitumor effect in ovarian cancer. <i>Molecular Cancer Therapeutics</i> , <b>2014</b> , 13, 1750-7  | 6.1                             | 23                     |
| 20                   | Bisphosphonates inhibit stellate cell activity and enhance antitumor effects of nanoparticle albumin-bound paclitaxel in pancreatic ductal adenocarcinoma. <i>Molecular Cancer Therapeutics</i> , <b>2014</b> , 13, 2583-94  | 6.1                             | 21                     |
| 19                   | Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens. JCI Insight, 2017, 2,  | 9.9                             | 20                     |
| 18                   | SSRI use and clinical outcomes in epithelial ovarian cancer. <i>Oncotarget</i> , <b>2016</b> , 7, 33179-91   | 3.3                             | 18                     |
| 17                   | Neuroendocrine Regulation of Tumor-Associated Immune Cells. <i>Frontiers in Oncology</i> , <b>2019</b> , 9, 1077   | 5.3                             | 14                     |
|                      |  |                                 |                        |
| 16                   | Why stress is BAD for cancer patients. <i>Journal of Clinical Investigation</i> , <b>2013</b> , 123, 558-60  | 15.9                            | 12                     |
| 16<br>15             | Why stress is BAD for cancer patients. <i>Journal of Clinical Investigation</i> , <b>2013</b> , 123, 558-60  PTEN Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer. <i>Molecular Cancer Therapeutics</i> , <b>2015</b> , 14, 1466-1475  | 15.9                            | 12                     |
|                      | PTEN Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer.  |                                 |                        |
| 15                   | PTEN Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer.  Molecular Cancer Therapeutics, 2015, 14, 1466-1475  Norepinephrine-Induced DNA Damage in Ovarian Cancer Cells. International Journal of Molecular   | 6.1                             | 11                     |
| 15<br>14             | PTEN Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer.  Molecular Cancer Therapeutics, 2015, 14, 1466-1475  Norepinephrine-Induced DNA Damage in Ovarian Cancer Cells. International Journal of Molecular Sciences, 2020, 21,  Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic   | 6.1                             | 11                     |
| 15<br>14<br>13       | PTEN Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer. <i>Molecular Cancer Therapeutics</i> , <b>2015</b> , 14, 1466-1475  Norepinephrine-Induced DNA Damage in Ovarian Cancer Cells. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,  Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer. <i>Molecular Cancer Therapeutics</i> , <b>2015</b> , 14, 2677-86  Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine   | 6.1<br>6.3<br>6.1               | 11<br>9<br>8           |
| 15<br>14<br>13       | PTEN Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer. <i>Molecular Cancer Therapeutics</i> , <b>2015</b> , 14, 1466-1475  Norepinephrine-Induced DNA Damage in Ovarian Cancer Cells. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,  Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer. <i>Molecular Cancer Therapeutics</i> , <b>2015</b> , 14, 2677-86  Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies. <i>Journal of the National Cancer Institute</i> , <b>2017</b> , 109,  Zoledronic Acid Abrogates Restraint Stress-Induced Macrophage Infiltration, PDGF-AA Expression,   | 6.1<br>6.3<br>6.1               | 11<br>9<br>8<br>7      |
| 15<br>14<br>13<br>12 | PTEN Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer. <i>Molecular Cancer Therapeutics</i> , <b>2015</b> , 14, 1466-1475  Norepinephrine-Induced DNA Damage in Ovarian Cancer Cells. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,  Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer. <i>Molecular Cancer Therapeutics</i> , <b>2015</b> , 14, 2677-86  Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies. <i>Journal of the National Cancer Institute</i> , <b>2017</b> , 109,  Zoledronic Acid Abrogates Restraint Stress-Induced Macrophage Infiltration, PDGF-AA Expression, and Ovarian Cancer Growth. <i>Cancers</i> , <b>2020</b> , 12, | 6.1<br>6.3<br>6.1<br>9.7<br>6.6 | 11<br>9<br>8<br>7<br>6 |

## LIST OF PUBLICATIONS

| 7 | Prevalence of breast and ovarian cancer subtypes in Hispanic populations from Puerto Rico. <i>BMC Cancer</i> , <b>2018</b> , 18, 1177   | 4.8  | 2 |  |
|---|---|------|---|--|
| 6 | Effects of long-term norepinephrine treatment on normal immortalized ovarian and fallopian tube cells. <i>Scientific Reports</i> , <b>2021</b> , 11, 14334                    | 4.9  | Ο |  |
| 5 | E2F3 drives the epithelial-to-mesenchymal transition, cell invasion, and metastasis in breast cancer. <i>Experimental Biology and Medicine</i> , <b>2021</b> , 246, 2057-2071 | 3.7  | О |  |
| 4 | Catecholamine-Induced DNA Damage in Ovarian Cancer Cells. FASEB Journal, 2020, 34, 1-1  | 0.9  |   |  |
| 3 | Editorld Note: Targeting Src in Mucinous Ovarian Carcinoma. Clinical Cancer Research, 2021, 27, 4450  | 12.9 |   |  |
| 2 | Editorঙ Note: Therapeutic Targeting of ATP7B in Ovarian Carcinoma. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 4454   | 12.9 |   |  |
| 1 | Editorህ Note: Functional Roles of and in Ovarian Carcinoma. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 4452  | 12.9 |   |  |